-
Telomere length as biomarker of nutritional therapy for prevention of type 2 diabetes mellitus development in patients with coronary heart disease: CORDIOPREV randomised controlled trial Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-16 Ana Ojeda-Rodriguez, Oriol A. Rangel-Zuñiga, Antonio P. Arenas-de Larriva, Francisco M. Gutierrez-Mariscal, Jose D. Torres-Peña, Juan L. Romero-Cabrera, Alicia Podadera-Herreros, Helena García-Fernandez, Esther Porras-Pérez, Raul M. Luque, Stefanos N. Kales, Pablo Perez-Martinez, Javier Delgado-Lista, Elena M. Yubero-Serrano, Jose Lopez-Miranda
Telomere Length (TL), a marker of cellular aging, holds promise as a biomarker to elucidate the molecular mechanism of diabetes. This study aimed to investigate whether shorter telomeres are associated with a higher risk of type 2 diabetes mellitus (T2DM) incidence in patients with coronary heart disease; and to determine whether the most suitable dietary patterns, particularly a Mediterranean diet
-
Hepatic insulin resistance and muscle insulin resistance are characterized by distinct postprandial plasma metabolite profiles: a cross-sectional study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-16 Anouk Gijbels, Balázs Erdős, Inez Trouwborst, Kelly M. Jardon, Michiel E. Adriaens, Gijs H. Goossens, Ellen E. Blaak, Edith J. M. Feskens, Lydia A. Afman
Tissue-specific insulin resistance (IR) predominantly in muscle (muscle IR) or liver (liver IR) has previously been linked to distinct fasting metabolite profiles, but postprandial metabolite profiles have not been investigated in tissue-specific IR yet. Given the importance of postprandial metabolic impairments in the pathophysiology of cardiometabolic diseases, we compared postprandial plasma metabolite
-
MCT4-dependent lactate transport: a novel mechanism for cardiac energy metabolism injury and inflammation in type 2 diabetes mellitus Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-14 Xiu Mei Ma, Kang Geng, Peng Wang, Zongzhe Jiang, Betty Yuen-Kwan Law, Yong Xu
Diabetic cardiomyopathy (DCM) is a major contributor to mortality in diabetic patients, characterized by a multifaceted pathogenesis and limited therapeutic options. While lactate, a byproduct of glycolysis, is known to be significantly elevated in type 2 diabetes, its specific role in DCM remains uncertain. This study reveals an abnormal upregulation of monocarboxylate transporter 4 (MCT4) on the
-
Association between triglyceride-glucose index and intracranial/extracranial atherosclerotic stenosis: findings from a retrospective study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-14 Yu Xie, Kuan Cen, Bitang Dan, Li Zou, Lei Zhang, Renwei Zhang, Huagang Li, Qi Cai, Nadire Aiziretiaili, Zhenxing Liu, Yumin Liu
The association of the triglyceride-glucose (TyG) index with intracranial atherosclerotic stenosis (ICAS) and extracranial atherosclerotic stenosis (ECAS) is unclear. This study aimed to investigate the relationship of TyG index with the distribution and severity of ICAS and ECAS. Patients who underwent digital subtraction angiography (DSA) for evaluating ICAS/ECAS in Zhongnan Hospital of Wuhan University
-
Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-11 Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, Alessandra Scatteia, Giandomenico Bisaccia, Salvatore De Rosa, Santo Dellegrottaglie, Chiara Bucciarelli-Ducci, Daniele Torella, Isabella Leo
Originally designed as anti-hyperglycemic drugs, Glucagon-Like Peptide-1 receptor agonists (GLP-1Ra) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated protective cardiovascular effects, with significant impact on cardiovascular morbidity and mortality. Despite several mechanisms have been proposed, the exact pathophysiology behind these effects is not yet fully understood. Cardiovascular
-
The relative and combined ability of stress hyperglycemia ratio and N-terminal pro-B-type natriuretic peptide to predict all-cause mortality in diabetic patients with multivessel coronary artery disease Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-11 Le Wang, Chen Wang, Jia-chun Lang, Rong-di Xu, Hong‑liang Cong, Jing‑xia Zhang, Yue‑cheng Hu, Ting-ting Li, Chun-wei Liu, Hua Yang, Wen‑yu Li
Stress hyperglycemia ratio (SHR) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are independently associated with increased mortality risk in diabetic patients with coronary artery disease (CAD). However, the role of these biomarkers in patients with diabetes and multivessel disease (MVD) remains unknown. The present study aimed to assess the relative and combined abilities of these biomarkers
-
Sex differences in the relationship between serum total bilirubin and risk of incident metabolic syndrome in community-dwelling adults: Propensity score analysis using longitudinal cohort data over 16 years Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-11 Ae Hee Kim, Da-Hye Son, Mid-Eum Moon, Soyoung Jeon, Hye Sun Lee, Yong-Jae Lee
Research on identifiable risks for metabolic syndrome (MetS) is ongoing, and growing evidence suggests that bilirubin is a potent antioxidant and cytoprotective agent against MetS. However, there have been conflicting results on the association between bilirubin and MetS. Our study aimed to validate the association by separately stratifying data for men and women in a longitudinal prospective study
-
Use of the energy waveform electrocardiogram to detect subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-06 Cheng Hwee Soh, Alex G. C. de Sá, Elizabeth Potter, Amera Halabi, David B. Ascher, Thomas H. Marwick
Recent guidelines propose N-terminal pro-B-type natriuretic peptide (NT-proBNP) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes mellitus (T2DM). Wavelet Transform based signal-processing transforms electrocardiogram (ECG) waveforms into an energy distribution waveform (ew)ECG, providing frequency and energy features that machine learning
-
The worsening effect of paroxysmal atrial fibrillation on left ventricular function and deformation in type 2 diabetes mellitus patients: a 3.0 T cardiovascular magnetic resonance feature tracking study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-06 Xue-Ming Li, Wei-Feng Yan, Ke Shi, Rui Shi, Li Jiang, Yue Gao, Chen-Yan Min, Xiao-Jing Liu, Ying-Kun Guo, Zhi-Gang Yang
Atrial fibrillation (AF) has been linked to an increased risk of cardiovascular death, overall mortality and heart failure in patients with type 2 diabetes mellitus (T2DM). The present study investigated the additive effects of paroxysmal AF on left ventricular (LV) function and deformation in T2DM patients with or without AF using the cardiovascular magnetic resonance feature tracking (CMR-FT) technique
-
Mean platelet volume (MPV) as new marker of diabetic macrovascular complications in patients with different glucose homeostasis Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-02 Velia Cassano, Giuseppe Armentaro, Domenico Iembo, Sofia Miceli, Teresa V. Fiorentino, Elena Succurro, Maria Perticone, Franco Arturi, Marta L. Hribal, Tiziana Montalcini, Francesco Andreozzi, Giorgio Sesti, Arturo Pujia, Angela Sciacqua
Platelets play an important role in the development of cardiovascular disease (CVD). Mean platelet volume (MPV) is considered as biological marker of platelets activity and function. The aim of the present study was to evaluate MPV values and its possible correlation with arterial stiffness and subclinical myocardial damage, in normal glucose tolerance patients (NGT), in newly diagnosed type 2 diabetic
-
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-29 Ellen Vercalsteren, Dimitra Karampatsi, Carolina Buizza, Thomas Nyström, Thomas Klein, Gesine Paul, Cesare Patrone, Vladimer Darsalia
Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities. Currently, there are no therapies targeting this important clinical problem. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are potent anti-diabetic drugs that also efficiently reduce cardiovascular death and heart failure. In addition, SGLT2i facilitate several processes implicated in stroke recovery. However,
-
Non-insulin-based insulin resistance indexes in predicting atrial fibrillation recurrence following ablation: a retrospective study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-28 Zhe Wang, Haoming He, Yingying Xie, Jiaju Li, Fangyuan Luo, Zhaowei Sun, Shuwen Zheng, Furong Yang, Xuexi Li, Xiaojie Chen, Yingwei Chen, Yihong Sun
Insulin resistance (IR) is involved in the pathophysiological processes of arrhythmias. Increasing evidence suggests triglyceride and glucose (TyG) index, metabolic score for insulin resistance (METS-IR), triglyceride glucose-body mass index (TyG-BMI), and triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio are simple and reliable surrogates for IR. Although they have been associated
-
Association between different insulin resistance surrogates and all-cause mortality in patients with coronary heart disease and hypertension: NHANES longitudinal cohort study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-28 Xin-Zheng Hou, Yan-Fei Lv, Yu-Shan Li, Qian Wu, Qian-Yu Lv, Ying-Tian Yang, Lan-Lan Li, Xue-Jiao Ye, Chen-Yan Yang, Man-Shi Wang, Lin-Lin Cao, Shi-Han Wang
Studies on the relationship between insulin resistance (IR) surrogates and long-term all-cause mortality in patients with coronary heart disease (CHD) and hypertension are lacking. This study aimed to explore the relationship between different IR surrogates and all-cause mortality and identify valuable predictors of survival status in this population. The data came from the National Health and Nutrition
-
Fatty liver index is an independent risk factor for all-cause mortality and major cardiovascular events in type 1 diabetes: an 11-year observational study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-28 Monia Garofolo, Daniela Lucchesi, Massimo Giambalvo, Michele Aragona, Alessandra Bertolotto, Fabrizio Campi, Cristina Bianchi, Paolo Francesconi, Piero Marchetti, Stefano Del Prato, Giuseppe Penno
Non-alcoholic fatty liver disease (NAFLD), identified by the Fatty Liver Index (FLI), is associated with increased mortality and cardiovascular (CV) outcomes. Whether this also applies to type 1 diabetes (T1D) has not been yet reported. We prospectively observed 774 subjects with type 1 diabetes (males 52%, 30.3 ± 11.1 years old, diabetes duration (DD) 18.5 ± 11.6 years, HbA1c 7.8 ± 1.2%) to assess
-
The prognostic value of the stress hyperglycemia ratio for all-cause and cardiovascular mortality in patients with diabetes or prediabetes: insights from NHANES 2005–2018 Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-28 Lei Ding, Hongda Zhang, Cong Dai, Aikai Zhang, Fengyuan Yu, Lijie Mi, Yingjie Qi, Min Tang
The Stress hyperglycemia ratio (SHR) is a novel marker reflecting the true acute hyperglycemia status and is associated with clinical adverse events. The relationship between SHR and mortality in patients with diabetes or prediabetes is still unclear. This study aimed to investigate the predictive value of the SHR for all-cause and cardiovascular mortality in patients with diabetes or prediabetes.
-
Distribution and prognostic value of high-sensitivity cardiac troponin T and I across glycemic status: a population-based study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-24 Jiajun Zhang, Xiaoxing Li, Shenglin Zhang, Zhen Wang, Rui Tian, Feng Xu, Yuguo Chen, Chuanbao Li
Whether distributions and prognostic values of high-sensitivity cardiac troponin (hs-cTn) T and I are different across normoglycemic, prediabetic, and diabetic populations is unknown. 10127 adult participants from the National Health and Nutrition Examination Survey 1999–2004 with determined glycemic status and measurement of at least one of hs-cTn assays were included, from whom healthy participants
-
Intensive lifestyle intervention in type 2 diabetes and risk of incident coronary artery disease for the common haptoglobin phenotypes: the Look AHEAD study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-24 Rachel A. Warren, Michael P. Bancks, Allie S. Carew, Andrew P. Levy, John Sapp, Judy Bahnson, Cora E. Lewis, Eric B. Rimm, Mark A. Espeland, Leah E. Cahill
Intensive glycemic control reduced coronary artery disease (CAD) events among the Action to Control Cardiovascular Disease Risk in Diabetes (ACCORD) participants with the haptoglobin (Hp) 2-2 phenotype only. It remains unknown whether Hp phenotype modifies the effect of an intensive lifestyle intervention (ILI) on CAD in type 2 diabetes. Haptoglobin phenotype was measured in 4542 samples from the Action
-
Link between triglyceride-glucose-body mass index and future stroke risk in middle-aged and elderly chinese: a nationwide prospective cohort study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-24 Yuankai Shao, Haofei Hu, Qiming Li, Changchun Cao, Dehong Liu, Yong Han
Current literature is deficient in robust evidence delineating the correlation between the triglyceride glucose-body mass index (TyG-BMI) and the incidence of stroke. Consequently, this investigation seeks to elucidate the potential link between TyG-BMI and stroke risk in a cohort of middle-aged and senior Chinese individuals. This study employs longitudinal data from four waves of the China Health
-
Association of the triglyceride-glucose index with all-cause and cardiovascular mortality in patients with cardiometabolic syndrome: a national cohort study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-24 Quanjun Liu, Yeshen Zhang, Shuhua Chen, Hong Xiang, Jie Ouyang, Huiqin Liu, Jing Zhang, Yanfei Chai, Zishun Zhan, Peng Gao, Xiao Zhang, Jianing Fan, Xinru Zheng, Zhihui Zhang, Hongwei Lu
This study aimed to evaluate the association of triglyceride-glucose (TyG) index with all-cause and cardiovascular mortality risk among patients with cardiometabolic syndrome (CMS). We performed a cohort study of 5754 individuals with CMS from the 2001–2018 National Health and Nutrition Examination Survey. The TyG index was calculated as Ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2]
-
Insulin resistance and coronary inflammation in patients with coronary artery disease: a cross-sectional study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-24 Tingjie Yang, Guoyong Li, Che Wang, Guian Xu, Qingman Li, Yapan Yang, Lijie Zhu, Lulin Chen, Xueqing Li, Honghui Yang
Insulin resistance (IR) is associated with coronary artery disease (CAD) severity. However, its underlying mechanisms are not fully understood. Therefore, our study aimed to explore the relationship between IR and coronary inflammation and investigate the synergistic and mediating effects of coronary inflammation on the association between IR and CAD severity. Consecutive patients with CAD who underwent
-
Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i—Arrhythmias and Sudden Cardiac Death) Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-24 Jia Liao, Ramin Ebrahimi, Zhiyu Ling, Christian Meyer, Martin Martinek, Philipp Sommer, Piotr Futyma, Davide Di Vece, Alexandra Schratter, Willem-Jan Acou, Lin Zhu, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Helmut Pürerfellner, Christian Templin, Shaojie Chen
We aimed to assess the effect of SGLT2i on arrhythmias by conducting a meta-analysis using data from randomized controlled trials(RCTs). Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have shown cardioprotective effects via multiple mechanisms that may also contribute to decrease arrhythmias risk. We searched in databases (PubMed, Embase, Cochrane Library, and clinicaltrials.gov) up to April 2023
-
The association between the AIP and undiagnosed diabetes in ACS patients with different body mass indexes and LDL-C levels: findings from the CCC-ACS project Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-20 Shuwan Xu, Jun Liu, Dong Zhao, Na Yang, Yongchen Hao, Yan Zhou, Dan Zhu, Ming Cui
The atherogenic index of plasma (AIP) has been demonstrated to be significantly associated with the incidence of prediabetes and diabetes. This study aimed to investigate the association between the AIP and undiagnosed diabetes in acute coronary syndrome (ACS) patients. Among 113,650 ACS patients treated with coronary angiography at 240 hospitals in the Improving Care for Cardiovascular Disease in
-
Associations of the triglyceride-glucose index and atherogenic index of plasma with the severity of new-onset coronary artery disease in different glucose metabolic states Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-20 Xiaosheng Wu, Weiping Qiu, Huancheng Yang, Yan-Jun Chen, Jianling Liu, Guojun Zhao
The triglyceride-glucose (TyG) index is considered a dependable biomarker for gauging insulin resistance. The atherogenic index of plasma (AIP) represents a marker reflecting atherosclerosis. However, there is currently no study specifically exploring the associations of these two biomarkers with the severity of new-onset coronary artery disease (CAD) under different glucose metabolic states. Therefore
-
Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-20 Inés Valencia, Jairo Lumpuy-Castillo, Giselle Magalhaes, Carlos F. Sánchez-Ferrer, Óscar Lorenzo, Concepción Peiró
Early since the onset of the COVID-19 pandemic, the medical and scientific community were aware of extra respiratory actions of SARS-CoV-2 infection. Endothelitis, hypercoagulation, and hypofibrinolysis were identified in COVID-19 patients as subsequent responses of endothelial dysfunction. Activation of the endothelial barrier may increase the severity of the disease and contribute to long-COVID syndrome
-
Correction: Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-20 Monica Gamez, Hesham E. Elhegni, Sarah Fawaz, Kwan Ho Ho, Neill W. Campbell, David A. Copland, Karen L. Onions, Matthew J. Butler, Elizabeth J. Wasson, Michael Crompton, Raina D. Ramnath, Yan Qiu, Yu Yamaguchi, Kenton P. Arkill, David O. Bates, Jeremy E. Turnbull, Olga V. Zubkova, Gavin I. Welsh, Denize Atan, Simon C. Satchell, Rebecca R. Foster
Following publication of the original article [1], the author noticed the error in Discussion section. In the last paragraph under Discussion section, the sentence “The heterogenous nature of oligo-/polysaccharide derivatives such as PG545 also results in batch variations, further complicating FDA approval” is incorrect. In this text, PG545 should be replaced with SST0001 and should read “The heterogenous
-
Prognostic effect of stress hyperglycemia ratio on patients with severe aortic stenosis receiving transcatheter aortic valve replacement: a prospective cohort study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-16 Xiangming Hu, Dejing Feng, Yuxuan Zhang, Can Wang, Yang Chen, Guannan Niu, Zheng Zhou, Zhenyan Zhao, Hongliang Zhang, Moyang Wang, Yongjian Wu
Stress hyperglycemia ratio (SHR) has recently been recognized as a novel biomarker that accurately reflects acute hyperglycemia status and is associated with poor prognosis of heart failure. We evaluated the relationship between SHR and clinical outcomes in patients with severe aortic stenosis receiving transcatheter aortic valve replacement (TAVR). There were 582 patients with severe native aortic
-
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-15 Muhammad Usman Ali, G. B. John Mancini, Donna Fitzpatrick-Lewis, Kim A. Connelly, Eileen O’Meara, Shelley Zieroth, Diana Sherifali
The 2022 Canadian Cardiovascular Society (CCS) cardiorenal guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) use. Since then, additional trials of relevance for SGLT2i have been published. This update re-evaluates the clinical recommendations for using SGLTi and their indirect comparison with existing
-
Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-15 Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol-Young Park
We assessed the efficacy and safety of enavogliflozin (0.3 mg), a newly developed SGLT-2 inhibitor, in patients with type 2 diabetes mellitus based on kidney function via pooled analysis of two 24-week, randomized, double-blind phase III trials. Data from 470 patients were included (enavogliflozin: 0.3 mg/day, n = 235; dapagliflozin: 10 mg/day, n = 235). The subjects were classified by mildly reduced
-
Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-15 Resham L. Gurung, Sylvia Liu, Jian-Jun Liu, Yiamunaa M., Huili Zheng, Clara Chan, Keven Ang, Tavintharan Subramaniam, Chee Fang Sum, Su Chi Lim
Angiogenin, an enzyme belonging to the ribonucleases A superfamily, plays an important role in vascular biology. Here, we sought to study the association of plasma angiogenin and major adverse cardiovascular events (MACEs) in patients with type 2 diabetes (T2D). This prospective study included 1083 T2D individuals recruited from a secondary hospital and a primary care facility. The primary outcome
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-13 Damien Denimal, Maharajah Ponnaiah, Anne-Caroline Jeannin, Franck Phan, Agnès Hartemann, Samia Boussouar, Etienne Charpentier, Alban Redheuil, Fabienne Foufelle, Olivier Bourron
Studies have demonstrated that coronary artery calcification on one hand and non-alcoholic fatty liver disease (NAFLD) on the other hand are strongly associated with cardiovascular events. However, it remains unclear whether NAFLD biomarkers could help estimate cardiovascular risk in individuals with type 2 diabetes (T2D). The primary objective of the present study was to investigate whether the biomarkers
-
DNA methylation risk score for type 2 diabetes is associated with gestational diabetes Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-13 Teresa M. Linares-Pineda, Nicolas Fragoso-Bargas, María José Picón, Maria Molina-Vega, Anne Karen Jenum, Line Sletner, Sindre Lee-Ødegård, Julia O. Opsahl, Gunn-Helen Moen, Elisabeth Qvigstad, Rashmi B. Prasad, Kåre I. Birkeland, Sonsoles Morcillo, Christine Sommer
Gestational diabetes mellitus (GDM) and type 2 diabetes mellitus (T2DM) share many pathophysiological factors including genetics, but whether epigenetic marks are shared is unknown. We aimed to test whether a DNA methylation risk score (MRS) for T2DM was associated with GDM across ancestry and GDM criteria. In two independent pregnancy cohorts, EPIPREG (n = 480) and EPIDG (n = 32), DNA methylation
-
Stress hyperglycemia ratio as a prognostic indicator for long-term adverse outcomes in heart failure with preserved ejection fraction Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-13 Abdul-Quddus Mohammed, Yongqiang Luo, Kaitao Wang, Yang Su, Lu Liu, Guoqing Yin, Wen Zhang, J Jiasuer. Alifu, Redhwan M. Mareai, Ayman A. Mohammed, Yawei Xu, Fuad A. Abdu, Wenliang Che
Recent studies highlighted that stress hyperglycemia ratio (SHR) is a potential predictor for future risk in heart failure (HF) patients. However, its implications specifically in HF with preserved ejection fraction (HFpEF) are not yet fully elucidated. We aimed to investigate the association between SHR and long-term clinical outcomes in HFpEF patients. HFpEF patients enrolled between 2015 and 2023
-
Association of the triglyceride glucose index with all-cause and cardiovascular mortality in a general population of Iranian adults Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-12 Ghazaal Alavi Tabatabaei, Noushin Mohammadifard, Hamed Rafiee, Fatemeh Nouri, Asieh Maghami mehr, Jamshid Najafian, Masoumeh Sadeghi, Maryam Boshtam, Hamidreza Roohafza, Fahimeh Haghighatdoost, Marzieh Taheri, Nizal Sarrafzadegan
The triglyceride glucose (TyG) index is a new and low-cost marker to determine insulin resistant which may be a predictor of cardiovascular disease (CVD). Although available evidence showed that its association with CVD mortality (CVM) and all-cause mortality (ACM) may differ in different populations, scarce data are available in this regard specially in low and middle-income countries. To examine
-
The double burden: type 1 diabetes and heart failure—a comprehensive review Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-12 María Teresa Julián, Alejandra Pérez-Montes de Oca, Josep Julve, Nuria Alonso
Heart failure (HF) is increasing at an alarming rate, primary due to the rising in aging, obesity and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated risk of HF, leading to more hospitalizations and increased case fatality rates. Several risk factors contribute to HF in T1D, including poor glycemic control, female gender, smoking, hypertension, elevated BMI,
-
The association between triglyceride glucose-body mass index and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study from MIMIC-IV database Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-10 Yi Hu, Yiting Zhao, Jing Zhang, Chaomin Li
The TyG-BMI index, which is a reliable indicator of insulin resistance (IR), has been found to have a significant correlation with the occurrence of cardiovascular events. However, there still lacks study on the TyG-BMI index and prognosis in patients with atrial fibrillation (AF). The objective of the present study was to evaluate the relationship between TyG-BMI index at admission to ICU and all-cause
-
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-10 Stephen J. Nicholls, Santiago Tofé, Carel W. le Roux, David A. D’Alessio, Russell J. Wiese, Imre Pavo, Katelyn Brown, Govinda J. Weerakkody, Meltem Zeytinoglu, Irene C. Romera
Metabolic syndrome is characterized as the co-occurrence of interrelated cardiovascular risk factors, including insulin resistance, hyperinsulinemia, abdominal obesity, dyslipidemia and hypertension. Once weekly tirzepatide is approved in the US and EU for the treatment of type 2 diabetes (T2D) and obesity. In the SURPASS clinical trial program for T2D, tirzepatide demonstrated greater improvements
-
Double diabetes—when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-10 Weronika Bielka, Agnieszka Przezak, Piotr Molęda, Ewa Pius-Sadowska, Bogusław Machaliński
Currently, the differentiation between type 1 diabetes (T1D) and type 2 diabetes (T2D) is not straightforward, and the features of both types of diabetes coexist in one subject. This situation triggered the need to discriminate so-called double diabetes (DD), hybrid diabetes or type 1.5 diabetes, which is generally described as the presence of the insulin resistance characteristic of metabolic syndrome
-
Simultaneous assessment of stress hyperglycemia ratio and glycemic variability to predict mortality in patients with coronary artery disease: a retrospective cohort study from the MIMIC-IV database Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-09 Hao-ming He, Shu-wen Zheng, Ying-ying Xie, Zhe Wang, Si-qi Jiao, Fu-rong Yang, Xue-xi Li, Jie Li, Yi-hong Sun
Stress hyperglycemia and glycemic variability (GV) can reflect dramatic increases and acute fluctuations in blood glucose, which are associated with adverse cardiovascular events. This study aimed to explore whether the combined assessment of the stress hyperglycemia ratio (SHR) and GV provides additional information for prognostic prediction in patients with coronary artery disease (CAD) hospitalized
-
Circulating exosomal mir-16-2-3p is associated with coronary microvascular dysfunction in diabetes through regulating the fatty acid degradation of endothelial cells Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-09 Yihai Liu, Chongxia Zhong, Shan Chen, Yanan Xue, Zhonghai Wei, Li Dong, Lina Kang
Coronary microvascular dysfunction (CMD) is a frequent complication of diabetes mellitus (DM) characterized by challenges in both diagnosis and intervention. Circulating levels of microRNAs are increasingly recognized as potential biomarkers for cardiovascular diseases. Serum exosomes from patients with DM, DM with coronary microvascular dysfunction (DM-CMD) or DM with coronary artery disease (DM-CAD)
-
Relationship between stress hyperglycaemic ratio and incidence of in-hospital cardiac arrest in patients with acute coronary syndrome: a retrospective cohort study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-09 Kui Li, Xueyuan Yang, Yunhang Li, Guanxue Xu, Yi Ma
The stress hyperglycaemic ratio (SHR), a new marker that reflects the true hyperglycaemic state of patients with acute coronary syndrome (ACS), is strongly associated with adverse clinical outcomes in these patients. Studies on the relationship between the SHR and in-hospital cardiac arrest (IHCA) incidence are limited. This study elucidated the relationship between the SHR and incidence of IHCA in
-
Protective role of arachidonic acid against diabetic myocardial ischemic injury: a translational study of pigs, rats, and humans Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-09 Yunhui Lv, Kai Li, Shuo Wang, Xiaokang Wang, Guangxin Yue, Yangyang Zhang, Xin Lv, Ping Zhao, Shiping Wang, Qi Zhang, Qiuju Li, Jinyan Zhu, Jubo Li, Peng Peng, Yue Li, Jiafei Luo, Xue Zhang, Jianzhong Yang, Baojie Zhang, Xuemin Wang, Min Zhang, Chen Shen, Xin Wang, Miao Wang, Zhen Ye, Yongchun Cui
Patients with diabetes mellitus have poor prognosis after myocardial ischemic injury. However, the mechanism is unclear and there are no related therapies. We aimed to identify regulators of diabetic myocardial ischemic injury. Mass spectrometry-based, non-targeted metabolomic approach was used to profile coronary sinus blood from diabetic and non-diabetic Bama-mini pigs at 0.5-h post coronary artery
-
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-08 Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno
No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reported the final-year results of the EMPRISE study, a monitoring program designed to evaluate the cardiorenal effectiveness of empagliflozin across broad patient subgroups. We
-
Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-08 Mototsugu Nagao, Jun Sasaki, Kyoko Tanimura-Inagaki, Ichiro Sakuma, Hitoshi Sugihara, Shinichi Oikawa
SGLT2 inhibitors and DPP4 inhibitors have been suggested to affect lipid metabolism. However, there are few randomized controlled trials comparing the effects on the lipid metabolism between the two types of antidiabetic drugs. The SUCRE study (UMIN ID: 000018084) was designed to compare the effects of ipragliflozin and sitagliptin on serum lipid and apolipoprotein profiles and other clinical parameters
-
The impact of prior exposure to hypoglycaemia on the inflammatory response to a subsequent hypoglycaemic episode Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-08 Clementine E. M. Verhulst, Julia I. P. van Heck, Therese W. Fabricius, Rinke Stienstra, Steven Teerenstra, Rory J. McCrimmon, Cees J. Tack, Ulrik Pedersen-Bjergaard, Bastiaan E. de Galan
Hypoglycaemia has been shown to induce a systemic pro-inflammatory response, which may be driven, in part, by the adrenaline response. Prior exposure to hypoglycaemia attenuates counterregulatory hormone responses to subsequent hypoglycaemia, but whether this effect can be extrapolated to the pro-inflammatory response is unclear. Therefore, we investigated the effect of antecedent hypoglycaemia on
-
Association between atherogenic index of plasma control level and incident cardiovascular disease in middle-aged and elderly Chinese individuals with abnormal glucose metabolism Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-08 Qianqian Min, Zhigang Wu, Jiangnan Yao, Siyi Wang, Lanzhi Duan, Sijia Liu, Mei Zhang, Yanhong Luo, Dongmei Ye, Yuxu Huang, Lan Chen, Ke Xu, Jianghua Zhou
The atherogenic index of plasma (AIP) and cardiovascular disease (CVD) in participants with abnormal glucose metabolism have been linked in previous studies. However, it was unclear whether AIP control level affects the further CVD incidence among with diabetes and pre-diabetes. Therefore, our study aimed to investigate the association between AIP control level with risk of CVD in individuals with
-
Association of plasma proteomics with incident coronary heart disease in individuals with and without type 2 diabetes: results from the population-based KORA study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-03 Hong Luo, Marie-Theres Huemer, Agnese Petrera, Stefanie M. Hauck, Wolfgang Rathmann, Christian Herder, Wolfgang Koenig, Annika Hoyer, Annette Peters, Barbara Thorand
Coronary heart disease (CHD) is a major global health concern, especially among individuals with type 2 diabetes (T2D). Given the crucial role of proteins in various biological processes, this study aimed to elucidate the aetiological role and predictive performance of protein biomarkers on incident CHD in individuals with and without T2D. The discovery cohort included 1492 participants from the Cooperative
-
Sirolimus-coated balloon in all-comer population of coronary artery disease patients: the EASTBOURNE DIABETES prospective registry Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-03 Gianluca Caiazzo, Angelo Oliva, Luca Testa, Tay M. Heang, Chuey Y. Lee, Diego Milazzo, Giulio Stefanini, Nicola Pesenti, Antonio Mangieri, Antonio Colombo, Bernardo Cortese
The outcomes of percutaneous coronary intervention (PCI) in diabetic patients are still suboptimal, and it is unclear if diabetic patients might derive a benefit from the use of drug-coated balloons. To evaluate the impact of diabetes mellitus on the outcomes of patients undergoing PCI with sirolimus-coated balloon (SCB) MagicTouch (Concept Medical, India). We conducted a subgroup analysis of the prospective
-
Revisiting an old relationship: the causal associations of the ApoB/ApoA1 ratio with cardiometabolic diseases and relative risk factors—a mendelian randomization analysis Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-03 Chao Fu, Dongbo Liu, Qi Liu, Xuedong Wang, Xiaoxue Ma, Hong Pan, Shi Feng, Zhao Sun, Weishen Qiao, Mengyue Yang, Shuang Gao, Hongyu Ding, Xingtao Huang, Jingbo Hou
It has been confirmed that the ApoB/ApoA1 ratio is closely associated with the incidence of cardiometabolic diseases (CMD). However, due to uncontrolled confounding factors in observational studies, the causal relationship of this association remains unclear. In this study, we extracted the ApoB/ApoA1 ratio and data on CMD and its associated risk factors from the largest European Genome-Wide Association
-
Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-01 Monica Gamez, Hesham E. Elhegni, Sarah Fawaz, Kwan Ho Ho, Neill W. Campbell, David A. Copland, Karen L. Onions, Matthew J. Butler, Elizabeth J. Wasson, Michael Crompton, Raina D. Ramnath, Yan Qiu, Yu Yamaguchi, Kenton P. Arkill, David O. Bates, Jeremy E. Turnbull, Olga V. Zubkova, Gavin I. Welsh, Denize Atan, Simon C. Satchell, Rebecca R. Foster
Diabetes mellitus is a chronic disease which is detrimental to cardiovascular health, often leading to secondary microvascular complications, with huge global health implications. Therapeutic interventions that can be applied to multiple vascular beds are urgently needed. Diabetic retinopathy (DR) and diabetic kidney disease (DKD) are characterised by early microvascular permeability changes which
-
Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-01 James L. Januzzi, Stefano Del Prato, Julio Rosenstock, Javed Butler, Justin Ezekowitz, Nasrien E. Ibrahim, Carolyn S.P. Lam, Thomas Marwick, W. H. Wilson Tang, Yuxi Liu, Reza Mohebi, Alessia Urbinati, Faiez Zannad, Riccardo Perfetti
Diabetic cardiomyopathy (DbCM) is a form of Stage B heart failure (HF) at high risk for progression to overt disease. Using baseline characteristics of study participants from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF) Trial we sought to characterize clinical characteristics of individuals with findings consistent with DbCM. Among study participants
-
The impact of type 2 diabetes mellitus on the clinical profile, myocardial fibrosis, and prognosis in non-ischemic dilated cardiomyopathy: a prospective cohort study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-01 Yangjie Li, Hong Xian, Yuanwei Xu, Weihao Li, Jiajun Guo, Ke Wan, Jie Wang, Ziqian Xu, Qing Zhang, Yuchi Han, Jiayu Sun, Yucheng Chen
The impact of the coexistence of type 2 diabetes mellitus (T2DM) in patients with non-ischemic dilated cardiomyopathy (DCM) on clinical profiles, myocardial fibrosis, and outcomes remain incompletely understood. A total of 1152 patients diagnosed with non-ischemic DCM were prospectively enrolled from June 2012 to October 2021 and categorized into T2DM and non-T2DM groups. Clinical characteristics,
-
Gestational diabetes mellitus and risk of long-term all-cause and cardiac mortality: a prospective cohort study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-01 Qian Ying, Yao Xu, Ziyi Zhang, Luyi Cai, Yan Zhao, Liping Jin
To investigate the association between gestational diabetes mellitus (GDM) without subsequent overt diabetes and long-term all-cause and cardiac mortality. This prospective cohort study included 10,327 women (weighted population: 132,332,187) with a pregnancy history from the National Health and Nutrition Examination Survey (2007 to 2018). Participants were divided into three groups (GDM alone, overt
-
Association of temporal change in body mass index with sudden cardiac arrest in diabetes mellitus Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-01-28 Joo Hee Jeong, Yun Gi Kim, Kyung-Do Han, Seung-Young Roh, Hyoung Seok Lee, Yun Young Choi, Jaemin Shim, Jong-Il Choi, Young-Hoon Kim
Underweight imposes significant burden on cardiovascular outcomes in patients with diabetes mellitus. However, less is known about the impact of serial change in body weight status measured as body mass index (BMI) on the risk of sudden cardiac arrest (SCA). This study investigated the association between SCA and temporal change in BMI among patients with diabetes mellitus. Based on Korean National
-
The role of mitochondrial DNA copy number in cardiometabolic disease: a bidirectional two-sample mendelian randomization study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-01-28 Pei Qin, Tianhang Qin, Lei Liang, Xinying Li, Bin Jiang, Xiaojie Wang, Jianping Ma, Fulan Hu, Ming Zhang, Dongsheng Hu
This study used a bidirectional 2-sample Mendelian randomization study to investigate the potential causal links between mtDNA copy number and cardiometabolic disease (obesity, hypertension, hyperlipidaemia, type 2 diabetes [T2DM], coronary artery disease [CAD], stroke, ischemic stroke, and heart failure). Genetic associations with mtDNA copy number were obtained from a genome-wide association study
-
Independent association of thigh muscle fat density with vascular events in Korean adults Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-01-28 Hun Jee Choe, Won Chang, Matthias Blüher, Steven B. Heymsfield, Soo Lim
We aimed to explore the associations between thigh muscle fat density and vascular events. A total of 3,595 adults (mean age, 57.2 years; women, 1,715 [47.7%]) without baseline cardiovascular events from the Korean Atherosclerosis Study-2 were included. Muscle and fat area at the mid-thigh level were measured by computed tomography (CT) using the following Hounsfield Unit range: 0–30 for low density
-
The association between TyG and all-cause/non-cardiovascular mortality in general patients with type 2 diabetes mellitus is modified by age: results from the cohort study of NHANES 1999–2018 Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-01-28 Younan Yao, Bo Wang, Tian Geng, Jiyan Chen, Wan Chen, Liwen Li
The prognostic value of triglyceride-glucose (TyG) index in general type 2 diabetes mellitus (T2DM) patients is still unclear. Therefore, we aimed to determine the associations between TyG and all-cause/cause-specific death in a T2DM cohort and explore whether such associations would be modified by age. A total of 3,376 patients with T2DM from the National Health and Nutrition Examination Survey (NHANES)
-
ASGR1 deficiency diverts lipids toward adipose tissue but results in liver damage during obesity Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-01-28 Monika Svecla, Lorenzo Da Dalt, Annalisa Moregola, Jasmine Nour, Andrea Baragetti, Patrizia Uboldi, Elena Donetti, Lorenzo Arnaboldi, Giangiacomo Beretta, Fabrizia Bonacina, Giuseppe Danilo Norata
Asialoglycoprotein receptor 1 (ASGR1), primarily expressed on hepatocytes, promotes the clearance and the degradation of glycoproteins, including lipoproteins, from the circulation. In humans, loss-of-function variants of ASGR1 are associated with a favorable metabolic profile and reduced incidence of cardiovascular diseases. The molecular mechanisms by which ASGR1 could affect the onset of metabolic
-
Prognostic implications of systemic immune-inflammation index in myocardial infarction patients with and without diabetes: insights from the NOAFCAMI-SH registry Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-01-22 Jiachen Luo, Xiaoming Qin, Xingxu Zhang, Yiwei Zhang, Fang Yuan, Wentao Shi, Baoxin Liu, Yidong Wei
It is well-known that systemic inflammation plays a crucial role in the pathogenesis and prognosis of acute myocardial infarction (AMI). The systemic immune-inflammation index (SII, platelet × neutrophil/lymphocyte ratio) is a novel index that is used for the characterization of the severity of systemic inflammation. Recent studies have identified the high SII level as an independent predictor of poor
-
The relationship between triglyceride-glucose index and prospective key clinical outcomes in patients hospitalised for coronary artery disease Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-01-22 Benchuan Hao, Lyu Lyu, Juan Xu, Xiaoqing Zhu, Cui Xu, Weiyang Gao, Ji Qin, Taoke Huang, Yipu Ding, Ziyue Zhang, Yanhui Yang, Hongbin Liu
The triglyceride-glucose (TyG) index is regarded as a dependable alternative for assessing insulin resistance (IR), given its simplicity, cost-effectiveness, and strong correlation with IR. The relationship between the TyG index and adverse outcomes in patients with coronary heart disease (CHD) is not well established. This study examines the association of the TyG index with long-term adverse outcomes
-
Association between the triglyceride-glucose index and impaired cardiovascular fitness in non-diabetic young population Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-01-20 Dachuan Guo, Zhenguo Wu, Fei Xue, Sha Chen, Xiangzhen Ran, Cheng Zhang, Jianmin Yang
The triglyceride-glucose (TyG) index has been linked to the onset, progression, and prognosis of cardiovascular disease (CVD) in middle-aged and elderly individuals. Nevertheless, the relationship between the TyG index and impaired cardiovascular fitness (CVF) remains unexplored in non-diabetic young population. We used data from the National Health and Nutrition Examination Survey (NHANES) study (1999–2004)